# EDGAR Filing Document

**Accession Number:** 0001945896
**File Stem:** 0000919574-26-004021
**Filing Date:** 2026-6
**Character Count:** 9763
**Document Hash:** bc4711fa02ddb34520a6fdee39a94ba6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000919574-26-004021.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0000919574-26-004021

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260610

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Domicilium Real Estate Fund III LP
- **CENTRAL INDEX KEY:** 0001945896

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31326
- **FILM NUMBER:** 261099465

**BUSINESS ADDRESS:**
- **STREET 1:** 215 EAST BAY ST, SUITE 203-E
- **CITY:** CHARLESTON
- **STATE:** SC
- **ZIP:** 29401
- **BUSINESS PHONE:** 800-308-5260

**MAIL ADDRESS:**
- **STREET 1:** 215 EAST BAY ST, SUITE 203-E
- **CITY:** CHARLESTON
- **STATE:** SC
- **ZIP:** 29401
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eloxx Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001035354
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 841368850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** P.O. BOX 274
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
- **BUSINESS PHONE:** 781-577-5300

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 274
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sevion Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20140930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SENESCO TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19991006

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NAVA LEISURE USA INC
- **DATE OF NAME CHANGE:** 19970310

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Domicilium Real Estate Fund III LP<br><sub>(Last) (First) (Middle)</sub><br>535 S. KIMBALL AVE, SUITE 140<br><sub>(Street)</sub><br>SOUTHLAKE, TX 76092<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-06-10 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eloxx Pharmaceuticals, Inc. [ ELOX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| common stock, $0.01 par value per share | 2026-06-10 |  | J<sup>(1)</sup> |  | 238422 | A | <sup>(1)</sup> | 238422 | I | See footnote<sup>(2)</sup> |
| common stock, $0.01 par value per share | 2026-06-10 |  | J<sup>(1)</sup> |  | 361578 | A | <sup>(1)</sup> | 361578 | I | See footnote<sup>(3)</sup> |
| common stock, $0.01 par value per share |  |  |  |  |  |  |  | 14285 | I | See footnote<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Pre-funded Warrant | <sup>(5)</sup> | 2026-06-10 |  | J<sup>(1)</sup> |  | 238422 |  | <sup>(5)</sup> | <sup>(5)</sup> | common stock, $0.01 par value per share | 238422 | <sup>(5)</sup> | 0 | I | See footnote<sup>(2)</sup> |
| Pre-funded Warrant | <sup>(5)</sup> | 2026-06-10 |  | J<sup>(1)</sup> |  | 361578 |  | <sup>(5)</sup> | <sup>(5)</sup> | common stock, $0.01 par value per share | 361578 | <sup>(5)</sup> | 834489 | I | See footnote<sup>(3)</sup> |
| Pre-funded Warrant | <sup>(5)</sup> |  |  |  |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | common stock, $0.01 par value per share | 0 |  | 361578 | I | See footnote<sup>(6)</sup> |
| Pre-funded Warrant | <sup>(5)</sup> |  |  |  |  |  |  | <sup>(5)</sup> | <sup>(5)</sup> | common stock, $0.01 par value per share | 0 |  | 611317 | I | See footnote<sup>(7)</sup> |

---

### Footnotes:

(1) Each pre-funded warrant to purchase shares of the Issuer's common stock (the "Pre-Funded Warrants") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock.

(2) The securities are owned directly by Domicilium Real Estate Fund III LP (the "Fund") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, ("Domicilium"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the "General Partner"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner.

(3) The securities are owned directly by BKJLAGG, LLC ("BKJLAGG") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium.

(4) The securities may be deemed to be indirectly beneficially owned by (i) Domicilium, and (ii) Daniel Simon, the managing member of Domicilium.

(5) The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise.

(6) The securities are owned directly by MSEK Charleston LLC ("MSEK") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to MSEK, and (ii) Daniel Simon, the managing member of Domicilium.

(7) The securities are owned directly by Bold Stroke Investments, LLC ("Bold Stroke") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to Bold Stroke, and (ii) Daniel Simon, the managing member of Domicilium.

**Remarks:**
Domicilium Capital Partners LLC, Domicilium Real Estate Fund III GP LLC, Daniel Simon, BKJLAGG, LLC, MSEK Charleston LLC and Bold Stroke Investments, LLC will be reported as a Reporting Person on a subsequent Form 4 once CIK codes are received.

Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

**Signature:** Domicilium Real Estate Fund III LP, By: Domicilium Real Estate Fund III GP LLC, its General Partner, By: /s/ Daniel Simon, Managing Member  
**Date:** 2026-06-17

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**